XTX Topco Ltd Acquires 1,558 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

XTX Topco Ltd boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 74.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,638 shares of the biopharmaceutical company’s stock after buying an additional 1,558 shares during the quarter. XTX Topco Ltd’s holdings in Regeneron Pharmaceuticals were worth $2,307,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Pinney & Scofield Inc. bought a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at about $25,000. E Fund Management Hong Kong Co. Ltd. lifted its position in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 31 shares during the last quarter. Tompkins Financial Corp bought a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at approximately $32,000. Curat Global LLC acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at approximately $32,000. Finally, American National Bank & Trust bought a new position in Regeneron Pharmaceuticals in the 1st quarter worth approximately $44,000. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on REGN shares. Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $700.00 to $580.00 in a research note on Friday, May 30th. Argus downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, June 30th. UBS Group boosted their price objective on shares of Regeneron Pharmaceuticals from $560.00 to $584.00 and gave the stock a “neutral” rating in a report on Friday, July 11th. The Goldman Sachs Group cut their price objective on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating for the company in a research report on Wednesday, April 30th. Finally, Royal Bank Of Canada downgraded Regeneron Pharmaceuticals from a “moderate buy” rating to a “hold” rating and set a $662.00 target price on the stock. in a research report on Friday, May 30th. One analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $837.61.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $554.58 on Thursday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. The stock has a market cap of $59.87 billion, a price-to-earnings ratio of 14.12, a PEG ratio of 2.09 and a beta of 0.33. The business has a 50 day simple moving average of $539.67 and a 200 day simple moving average of $606.17. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The firm’s revenue was down 3.7% on a year-over-year basis. During the same period in the prior year, the company earned $9.55 EPS. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.63%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.